NCT06356259View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants

PHASE1TerminatedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

June 7, 2023

Primary Completion Date

January 23, 2025

Study Completion Date

January 23, 2025

Conditions
Healthy Participants
Interventions
DRUG

IRX-010

Administered IV

DRUG

Placebo

Administered IV

Trial Locations (1)

9728

ICON, Groningen

Sponsors
All Listed Sponsors
lead

ImmunoRx Pharma Inc.

INDUSTRY

NCT06356259 - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants | Biotech Hunter | Biotech Hunter